In pre-clinical studies, olaparib has been shown to upregulate NKG2D ligand expression on the surface of the AML cell line, HL-60, and promoted the cytotoxicity of the NK cells [108]. The gene discussed is KLRK1; the disease is acute myeloid leukemia.